Algernon Pharmaceuticals Inc presents at the Proactive One2One virtual investment forum

Christopher J. Moreau, CEO of Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) presents to investors at the Proactive One2One virtual investment forum. Algernon is a clinical stage pharmaceutical development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). The company identifies drugs that are used to treat one condition but repurposes them for different treatments. Most recently the company is focusing its efforts on repurposing ifenprodil (NP-120) as a potential COVID-19 treatment. Algernon believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively.